BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 9914792)

  • 1. Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P-glycoprotein.
    Kusunoki N; Takara K; Tanigawara Y; Yamauchi A; Ueda K; Komada F; Ku Y; Kuroda Y; Saitoh Y; Okumura K
    Jpn J Cancer Res; 1998 Nov; 89(11):1220-8. PubMed ID: 9914792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of cyclosporin analogues and FK506 on transcellular transport of daunorubicin and vinblastine via P-glycoprotein.
    Tanaka K; Hirai M; Tanigawara Y; Yasuhara M; Hori R; Ueda K; Inui K
    Pharm Res; 1996 Jul; 13(7):1073-7. PubMed ID: 8842048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs.
    Takara K; Tanigawara Y; Komada F; Nishiguchi K; Sakaeda T; Okumura K
    Biol Pharm Bull; 1999 Dec; 22(12):1355-9. PubMed ID: 10746169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of P-glycoprotein-mediated vinblastine transport across HCT-8 intestinal carcinoma monolayers by verapamil, cyclosporine A and SDZ PSC 833 in dependence on extracellular pH.
    Zacherl J; Hamilton G; Thalhammer T; Riegler M; Cosentini EP; Ellinger A; Bischof G; Schweitzer M; Teleky B; Koperna T
    Cancer Chemother Pharmacol; 1994; 34(2):125-32. PubMed ID: 7910786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of docetaxel ("Taxotere") with human P-glycoprotein.
    Shirakawa K; Takara K; Tanigawara Y; Aoyama N; Kasuga M; Komada F; Sakaeda T; Okumura K
    Jpn J Cancer Res; 1999 Dec; 90(12):1380-6. PubMed ID: 10665657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel anticancer drug KRN5500 interacts with, but is hardly transported by, human P-glycoprotein.
    Takara K; Tanigawara Y; Komada F; Nishiguchi K; Sakaeda T; Okumura K
    Jpn J Cancer Res; 2000 Feb; 91(2):248-54. PubMed ID: 10761713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory effect of cyclosporin A on p-glycoprotein function in peripheral nerves of mice treated with doxorubicin and vinblastine.
    Saito T; Zhang ZJ; Ohtsubo T; Noda I; Tokuriki M; Shibamori Y; Yamamoto T; Saito H
    Acta Otolaryngol; 2004 Apr; 124(3):313-7. PubMed ID: 15141761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of alpha-adrenoceptor antagonist doxazosin on MDR1-mediated multidrug resistance and transcellular transport.
    Takara K; Sakaeda T; Kakumoto M; Tanigawara Y; Kobayashi H; Okumura K; Ohnishi N; Yokoyama T
    Oncol Res; 2009; 17(11-12):527-33. PubMed ID: 19806783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of carvedilol on MDR1-mediated multidrug resistance: comparison with verapamil.
    Kakumoto M; Sakaeda T; Takara K; Nakamura T; Kita T; Yagami T; Kobayashi H; Okamura N; Okumura K
    Cancer Sci; 2003 Jan; 94(1):81-6. PubMed ID: 12708479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P-glycoprotein-mediated multidrug resistance is modulated by pretreatment with chemosensitizers in HCT-8 carcinoma cells in vitro.
    Haberl I; Swatonek H; Schaufler K; Ulsperger E; Wenzl E; Theyer G; Hamilton G; Thalhammer T
    Int J Oncol; 1998 May; 12(5):1137-42. PubMed ID: 9538140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In situ transport of vinblastine and selected P-glycoprotein substrates: implications for drug-drug interactions at the mouse blood-brain barrier.
    Cisternino S; Rousselle C; Debray M; Scherrmann JM
    Pharm Res; 2004 Aug; 21(8):1382-9. PubMed ID: 15359572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines.
    van der Sandt IC; Blom-Roosemalen MC; de Boer AG; Breimer DD
    Eur J Pharm Sci; 2000 Sep; 11(3):207-14. PubMed ID: 11042226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening of multidrug-resistance sensitive drugs by in situ brain perfusion in P-glycoprotein-deficient mice.
    Cisternino S; Rousselle C; Dagenais C; Scherrmann JM
    Pharm Res; 2001 Feb; 18(2):183-90. PubMed ID: 11405289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo saturation of the transport of vinblastine and colchicine by P-glycoprotein at the rat blood-brain barrier.
    Cisternino S; Rousselle C; Debray M; Scherrmann JM
    Pharm Res; 2003 Oct; 20(10):1607-11. PubMed ID: 14620515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of placental P-glycoprotein: impact on indinavir transfer to the foetus.
    Sudhakaran S; Rayner CR; Li J; Kong DC; Gude NM; Nation RL
    Br J Clin Pharmacol; 2008 May; 65(5):667-73. PubMed ID: 18093255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems.
    Kawahara I; Kato Y; Suzuki H; Achira M; Ito K; Crespi CL; Sugiyama Y
    Drug Metab Dispos; 2000 Oct; 28(10):1238-43. PubMed ID: 10997946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined treatment of Bcl-2 antisense oligodeoxynucleotides (G3139), p-glycoprotein inhibitor (PSC833), and sterically stabilized liposomal doxorubicin suppresses growth of drug-resistant growth of drug-resistant breast cancer in severely combined immunodeficient mice.
    Lopes de Menezes DE; Hu Y; Mayer LD
    J Exp Ther Oncol; 2003; 3(2):72-82. PubMed ID: 12822513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo.
    Watanabe T; Tsuge H; Oh-Hara T; Naito M; Tsuruo T
    Acta Oncol; 1995; 34(2):235-41. PubMed ID: 7718262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of P-glycoprotein inhibitors on cadmium accumulation in cultured renal epithelial cells, LLC-PK1, and OK.
    Endo T; Kimura O; Sakata M
    Toxicol Appl Pharmacol; 2002 Dec; 185(3):166-71. PubMed ID: 12498733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Availability of PSC833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum.
    Smith AJ; Mayer U; Schinkel AH; Borst P
    J Natl Cancer Inst; 1998 Aug; 90(15):1161-6. PubMed ID: 9701366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.